SBIO

ALPS Medical Breakthroughs ETF

Down$34.92
$-1.69
(-4.62%)
As of 12:00:00 AM EDT | 3/22/19  |  Market Closed

SBIO Trading Data

Open

$36.41

Low Price

$34.91

High Price

$36.41

Previous Last Price

$36.61

Bid Size

$0 X 0

Ask Size

$0 X 0

SBIO Portfolio Data

AUM

$197,560,000

Shares

5,500

PE Ratio

12.55

Price / Book Ratio

3.39

Expense Ratio

0.5

Net Asset Value

$35.92

Volume

Volume

49,100

Avg. Volume (YDT)

43,511

Dollar Volume

$1,442,047

Weekly Avg. Volume

36,060

Monthly Avg. Volume

40,970

Quarterly Avg. Volume

50,543

SBIO Fund Description

The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.

SBIO Chart

SBIO Summary

Fund Family

ALPS Holdings

Tracks This Index

ALPS Medical Breakthroughs ETF

Inception Date

2015-01-05

Asset Class

Portfolio-Multi Asset

Asset Class Size

Healthcare

SBIO Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

SBIO Holdings

Top 10 Holdings

United Therapeutics Corp. (UTHR)
480%
Galapagos NV (GLPG)
451%
Array BioPharma Inc. (ARRY)
448%
Ascendis Pharma AS (ASND)
437%
Agios Pharmaceuticals Inc. (AGIO)
436%
FibroGen Inc. (FGEN)
425%
Immunomedics Inc. (IMMU)
419%
Global Blood Therapeutics Inc. (GBT)
346%
Ligand Pharmaceuticals Inc. (LGND)
321%
Mirati Therapeutics Inc. (MRTX)
314%

Total SBIO Holdings

Total Holdings: 72

United Therapeutics Corp. (UTHR)
480%
Galapagos NV (GLPG)
451%
Array BioPharma Inc. (ARRY)
448%
Ascendis Pharma AS (ASND)
437%
Agios Pharmaceuticals Inc. (AGIO)
436%
FibroGen Inc. (FGEN)
425%
Immunomedics Inc. (IMMU)
419%
Global Blood Therapeutics Inc. (GBT)
346%
Ligand Pharmaceuticals Inc. (LGND)
321%
Mirati Therapeutics Inc. (MRTX)
314%
Emergent BioSolutions Inc. (EBS)
311%
uniQure NV (QURE)
295%
Acceleron Pharma Inc. (XLRN)
286%
Halozyme Therapeutics Inc. (HALO)
283%
Insmed Inc. (INSM)
275%
PTC Therapeutics Inc. (PTCT)
272%
Arena Pharmaceuticals Inc. (ARNA)
269%
Madrigal Pharmaceuticals Inc. (MDGL)
260%
AnaptysBio Inc. (ANAB)
240%
Enanta Pharmaceuticals Inc. (ENTA)
233%
CRISPR Therapeutics AG (CRSP)
232%
Atara Biotherapeutics Inc. (ATRA)
215%
Apellis Pharmaceuticals Inc. (APLS)
134%
Fate Therapeutics Inc. (FATE)
131%
Rhythm Pharmaceuticals Inc. (RYTM)
130%
Akebia Therapeutics Inc. (AKBA)
123%
MacroGenics Inc. (MGNX)
116%
Vericel Corp. (VCEL)
99%
Cara Therapeutics Inc. (CARA)
91%
UroGen Pharma Ltd. (URGN)
88%
Acorda Therapeutics Inc. (ACOR)
79%
Viking Therapeutics Inc. (VKTX)
74%
Voyager Therapeutics Inc. (VYGR)
74%
NuCana PLC (NCNA)
73%
Kura Oncology Inc. (KURA)
71%
GlycoMimetics Inc. (GLYC)
70%
ChemoCentryx Inc. (CCXI)
69%
G1 Therapeutics Inc. (GTHX)
67%
ArQule Inc. (ARQL)
66%
PDL BioPharma Inc. (PDLI)
66%
Flexion Therapeutics Inc. (FLXN)
60%
Five Prime Therapeutics Inc. (FPRX)
58%
Corbus Pharmaceuticals Holdings Inc. (CRBP)
56%
AMAG Pharmaceuticals Inc. (AMAG)
53%
Catalyst Pharmaceuticals Inc. (CPRX)
52%
Achillion Pharmaceuticals Inc. (ACHN)
51%
Progenics Pharmaceuticals Inc. (PGNX)
46%
Concert Pharmaceuticals Inc. (CNCE)
46%
Krystal Biotech Inc. (KRYS)
45%
Abeona Therapeutics Inc. (ABEO)
45%
ImmunoGen Inc. (IMGN)
45%
Albireo Pharma Inc. (ALBO)
43%
MediciNova Inc. (MNOV)
42%
AC Immune SA (ACIU)
40%
Syros Pharmaceuticals Inc. (SYRS)
39%
CASI Pharmaceuticals Inc. (CASI)
37%
Minerva Neurosciences Inc. (NERV)
37%
Kiniksa Pharmaceuticals Ltd. (KNSA)
37%
Aduro Biotech Inc. (ADRO)
37%
Savara Inc. (SVRA)
35%
Xenon Pharmaceuticals Inc. (XENE)
31%
Calithera Biosciences Inc. (CALA)
31%
Tocagen Inc. (TOCA)
30%
MEI Pharma Inc. (MEIP)
27%
Athersys Inc. (ATHX)
27%
Adamas Pharmaceuticals Inc. (ADMS)
26%
Arbutus Biopharma Corp. (ABUS)
25%
Synlogic Inc. (SYBX)
24%
State Street Institutional Treasury Plus Money Market Fund (TPIXX)
5%
Cash and Equivalents
1%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Corium International Inc (CORI-CVR)
0%

SBIO Technicals

Alpha

-8.64

Beta

1.69

Leverage

Long

Standard Deviation

3.01

SBIO Dividends

Dividend Date

2018-12-20

Latest Dividend

0.784

Annual Dividend

0.78

Annual Dividend Rate

0.78

Annual Dividend Yield

2.18

SBIO Performance

YTD Return

24.09%

1 Year Return

-0.26%

3 Year Return

67.4%

5 Year Return

0%

10 Year Return

40.58%

SBIO Related Articles

A Nifty Biotech ETF Idea for 2018

A Nifty Biotech ETF Idea for 2018

Biotechnology stocks bolstered the broader healthcare sector last year, a theme that is expected to continue in 2018. Investors looking…